Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361952422> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W4361952422 abstract "<div>Abstract<p><b>Purpose:</b> Our previous work suggested that HER3 inhibition sensitizes head and neck squamous cell carcinoma (HNSCC) to EGFR inhibition with cetuximab. This study aimed to define the role of HER3 in cetuximab resistance and the antitumor mechanisms of EGFR/HER3 dual targeting in HNSCC.</p><p><b>Experimental Design:</b> We treated cetuximab-resistant HNSCC UMSCC1-C and parental UMSCC1-P cell lines with anti-EGFR antibody cetuximab, anti-HER3 antibody MM-121, and their combination. We assessed activities of HER2, HER3, and downstream signaling pathways by Western blotting and cell growth by sulforhodamine B (SRB) and colony formation assays. HER3-specific shRNA was used to confirm the role of HER3 in cetuximab response. The combined efficacy and alterations in biomarkers were evaluated in UMSCC1-C xenograft and patient-derived xenograft (PDX) models.</p><p><b>Results:</b> Cetuximab treatment induced HER3 activation and HER2/HER3 dimerization in HNSCC cell lines. Combined treatment with cetuximab and MM-121 blocked EGFR and HER3 activities and inhibited the PI3K/AKT and ERK signaling pathways and HNSCC cell growth more effectively than each antibody alone. HER3 knockdown reduced HER2 activation and resensitized cells to cetuximab. Cetuximab-resistant xenografts and PDX models revealed greater efficacy of dual EGFR and HER3 inhibition compared with single antibodies. In PDX tissue samples, cetuximab induced HER3 expression and MM-121 reduced AKT activity.</p><p><b>Conclusions:</b> Clinically relevant PDX models demonstrate that dual targeting of EGFR and HER3 is superior to EGFR targeting alone in HNSCC. Our study illustrates the upregulation of HER3 by cetuximab as one mechanism underlying resistance to EGFR inhibition in HNSCC, supporting further clinical investigations using multiple targeting strategies in patients who have failed cetuximab-based therapy. <i>Clin Cancer Res; 23(3); 677–86. ©2016 AACR</i>.</p></div>" @default.
- W4361952422 created "2023-04-05" @default.
- W4361952422 creator A5010399375 @default.
- W4361952422 creator A5019077694 @default.
- W4361952422 creator A5019774807 @default.
- W4361952422 creator A5022023254 @default.
- W4361952422 creator A5031944258 @default.
- W4361952422 creator A5036672833 @default.
- W4361952422 creator A5036760441 @default.
- W4361952422 creator A5042210553 @default.
- W4361952422 creator A5052071925 @default.
- W4361952422 creator A5052501124 @default.
- W4361952422 creator A5059710197 @default.
- W4361952422 creator A5066168392 @default.
- W4361952422 creator A5083126177 @default.
- W4361952422 creator A5083667162 @default.
- W4361952422 creator A5085137065 @default.
- W4361952422 date "2023-03-31" @default.
- W4361952422 modified "2023-09-27" @default.
- W4361952422 title "Data from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models" @default.
- W4361952422 doi "https://doi.org/10.1158/1078-0432.c.6525776.v1" @default.
- W4361952422 hasPublicationYear "2023" @default.
- W4361952422 type Work @default.
- W4361952422 citedByCount "0" @default.
- W4361952422 crossrefType "posted-content" @default.
- W4361952422 hasAuthorship W4361952422A5010399375 @default.
- W4361952422 hasAuthorship W4361952422A5019077694 @default.
- W4361952422 hasAuthorship W4361952422A5019774807 @default.
- W4361952422 hasAuthorship W4361952422A5022023254 @default.
- W4361952422 hasAuthorship W4361952422A5031944258 @default.
- W4361952422 hasAuthorship W4361952422A5036672833 @default.
- W4361952422 hasAuthorship W4361952422A5036760441 @default.
- W4361952422 hasAuthorship W4361952422A5042210553 @default.
- W4361952422 hasAuthorship W4361952422A5052071925 @default.
- W4361952422 hasAuthorship W4361952422A5052501124 @default.
- W4361952422 hasAuthorship W4361952422A5059710197 @default.
- W4361952422 hasAuthorship W4361952422A5066168392 @default.
- W4361952422 hasAuthorship W4361952422A5083126177 @default.
- W4361952422 hasAuthorship W4361952422A5083667162 @default.
- W4361952422 hasAuthorship W4361952422A5085137065 @default.
- W4361952422 hasBestOaLocation W43619524222 @default.
- W4361952422 hasConcept C121608353 @default.
- W4361952422 hasConcept C126322002 @default.
- W4361952422 hasConcept C159654299 @default.
- W4361952422 hasConcept C173396325 @default.
- W4361952422 hasConcept C185592680 @default.
- W4361952422 hasConcept C190232843 @default.
- W4361952422 hasConcept C190283241 @default.
- W4361952422 hasConcept C203014093 @default.
- W4361952422 hasConcept C2776530083 @default.
- W4361952422 hasConcept C2776833033 @default.
- W4361952422 hasConcept C2777506169 @default.
- W4361952422 hasConcept C2779438470 @default.
- W4361952422 hasConcept C2779998722 @default.
- W4361952422 hasConcept C502942594 @default.
- W4361952422 hasConcept C542903549 @default.
- W4361952422 hasConcept C55493867 @default.
- W4361952422 hasConcept C62478195 @default.
- W4361952422 hasConcept C71924100 @default.
- W4361952422 hasConcept C75217442 @default.
- W4361952422 hasConcept C86554907 @default.
- W4361952422 hasConceptScore W4361952422C121608353 @default.
- W4361952422 hasConceptScore W4361952422C126322002 @default.
- W4361952422 hasConceptScore W4361952422C159654299 @default.
- W4361952422 hasConceptScore W4361952422C173396325 @default.
- W4361952422 hasConceptScore W4361952422C185592680 @default.
- W4361952422 hasConceptScore W4361952422C190232843 @default.
- W4361952422 hasConceptScore W4361952422C190283241 @default.
- W4361952422 hasConceptScore W4361952422C203014093 @default.
- W4361952422 hasConceptScore W4361952422C2776530083 @default.
- W4361952422 hasConceptScore W4361952422C2776833033 @default.
- W4361952422 hasConceptScore W4361952422C2777506169 @default.
- W4361952422 hasConceptScore W4361952422C2779438470 @default.
- W4361952422 hasConceptScore W4361952422C2779998722 @default.
- W4361952422 hasConceptScore W4361952422C502942594 @default.
- W4361952422 hasConceptScore W4361952422C542903549 @default.
- W4361952422 hasConceptScore W4361952422C55493867 @default.
- W4361952422 hasConceptScore W4361952422C62478195 @default.
- W4361952422 hasConceptScore W4361952422C71924100 @default.
- W4361952422 hasConceptScore W4361952422C75217442 @default.
- W4361952422 hasConceptScore W4361952422C86554907 @default.
- W4361952422 hasLocation W43619524221 @default.
- W4361952422 hasLocation W43619524222 @default.
- W4361952422 hasOpenAccess W4361952422 @default.
- W4361952422 hasPrimaryLocation W43619524221 @default.
- W4361952422 hasRelatedWork W1964368483 @default.
- W4361952422 hasRelatedWork W2012349653 @default.
- W4361952422 hasRelatedWork W2039595652 @default.
- W4361952422 hasRelatedWork W2133007905 @default.
- W4361952422 hasRelatedWork W2288576450 @default.
- W4361952422 hasRelatedWork W2581581719 @default.
- W4361952422 hasRelatedWork W2774667864 @default.
- W4361952422 hasRelatedWork W3012822845 @default.
- W4361952422 hasRelatedWork W3159430777 @default.
- W4361952422 hasRelatedWork W2575240156 @default.
- W4361952422 isParatext "false" @default.
- W4361952422 isRetracted "false" @default.
- W4361952422 workType "article" @default.